Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ShotCAR-GRP94
- Development stage
- Preclinical
- Lead developer
- Hauul Bio
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-Macrophages → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ShotCAR-GRP94 is a preclinical-stage chimeric antigen receptor (CAR) cell therapy being developed by Hauul Bio for the treatment of various solid tumors. The therapy utilizes Hauul Bio's proprietary ShotCAR platform to engineer immune cells that specifically target Glucose-Regulated Protein 94 (GRP94), also known as Endoplasmin. GRP94 is a molecular chaperone that is frequently overexpressed on the surface of malignant cells in several cancers, including triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC), while maintaining limited expression in normal tissues. By targeting GRP94, ShotCAR-GRP94 aims to selectively eliminate tumor cells through immune-mediated lysis while minimizing off-target toxicity.
Beyond the preview
Go deeper on ShotCAR-GRP94.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ShotCAR-GRP94.